B6-hPCSK9 mice are a humanized model generated by gene editing technology to replace the mouse Pcsk9 gene with the human PCSK9 gene sequence. These mice express human PCSK9 protein and can be used for research on various metabolic diseases, neurodegenerative diseases, tumor development, autoimmune disease mechanisms, and for the preclinical pharmacological evaluation of PCSK9-targeted drugs. In addition, Cyagen has developed a similar model, the B6-hPCSK9(CDS) mouse (PCSK9 coding sequence humanized model, Catalog Number: C001593). Compared to the B6-hPCSK9 mouse model, the B6-hPCSK9(CDS) mouse expresses higher levels of human PCSK9 and exhibits LDLR protein expression closer to physiological levels. It is recommended to choose the appropriate model based on the type of drug or research direction.

The B6-hPCSK9/Apoe KO mice are obtained by crossing B6-hPCSK9 mice with B6J-Apoe KO mice. The B6-hPCSK9/Apoe KO mice, while expressing the human PCSK9 protein, exhibit significantly elevated cholesterol levels and spontaneous atherosclerosis characteristics. These mice provide an ideal platform for the PCSK9-targeted drug development in hyperlipidemia and cardiovascular diseases, demonstrating good clinical and pathological relevance.

The B6J-Apoe KO mouse is a model of ApoE deficiency. It was generated by gene editing technology to knock out the Apoe gene in mice. ApoE protein synthesis is blocked in these mice, leading to elevated cholesterol levels and spontaneous atherosclerosis. Cholesterol levels and atherosclerosis in mice fed a high-fat diet (HFD) are further exacerbated. The B6J-Apoe KO mice are viable and can be used for research in hypercholesterolemia, atherosclerosis, and Alzheimer's disease.